Trials of obeticholic acid for non-alcoholic steatohepatitis

The Lancet

Volumn 386, Issue 9988, 2015, Pages 27-

  Musso, Giovanni ^a   Cassader, Maurizio ^b   Gambino, Roberto ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OBETICHOLIC ACID; CHENODEOXYCHOLIC ACID;

DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; GLUCOSE INTOLERANCE; HUMAN; LETTER; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; FEMALE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

CHENODEOXYCHOLIC ACID; FEMALE; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84937219569     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61198-9     Document Type: Letter

References (4)

1. BA Neuschwander-Tetri, AJ Sanyal, JE Lavine et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965
2. S Mudaliar, RR Henry, AJ Sanyal et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 145 2013 574 582
3. G Musso, M Cassader, F Rosina, R Gambino Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials Diabetologia 55 2012 885 904
4. H Ma, ME Patti Bile acids, obesity, and the metabolic syndrome Best Pract Res Clin Gastroenterol 28 2014 573 583